DrugLib.com — Drug Information Portal

Rx drug information, pharmaceutical research, clinical trials, news, and more

Intraoperative daunorubicin to prevent the recurrence of pterygium after excision.

Author(s): Dadeya S, Kamlesh

Affiliation(s): Guru Nanak Eye Center, Maulana Azad Medical College, New Delhi, India.

Publication date & source: 2001-03, Cornea., 20(2):172-4.

Publication type: Clinical Trial; Randomized Controlled Trial

PURPOSE: This study examines the safety, efficacy, and complications of 0.02% intraoperative daunorubicin in the prevention of the recurrence of pterygium after excision. METHODS: Sixty patients with primary pterygium were included in this prospective, randomized clinical study and were randomly divided into two groups: the treatment group and the control group. Pterygium was excised under a microscope in all patients. The treatment group received intraoperative single application of 0.02% daunorubicin for 3 minutes, whereas the control group received distilled water for the same duration. Recurrence of pterygium and postoperative complications were prime areas of interest. RESULTS: A recurrence rate of 6.67% was seen in the treatment group and was 33% in the control group. Chemosis of conjunctiva and delayed epithelization were the only complications noticed after a mean follow-up of 15 months. CONCLUSION: Initial results indicate that a single intraoperative application of 0.02% daunorubicin for 3 minutes appears to be a safe and effective adjunct therapy to prevent the recurrence of pterygium. However, a much larger cohort study over a considerable number of years will eventually demonstrate the safety.

Page last updated: 2006-01-31

-- advertisement -- The American Red Cross
Home | About Us | Contact Us | Site usage policy | Privacy policy

All Rights reserved - Copyright DrugLib.com, 2006-2017